TP53 and acute myeloid leukemia: WHO authors did not deem that studies published to date were sufficient for including ‘TP53 mutated AML’ as a distinct entity as this would result in masking not just AML-MR but other types of AML that may harbor mutant TP53. Further studies are needed to definitely answer the open questions including whether all or a subtype of TP53 altered AML cases should be combined to a new (provisional) entity.